Anticoagulation Management in Warfarin-Related ICH in Patients with Mechanical Heart Valves

Introduction Warfarin‐associated intracranial hemorrhage (ICH) in patients with mechanical heart valves (MHV) is rare but serious, with an annual incidence of ∼0.5% [1]. Management requires balancing prevention of hemorrhage expansion through anticoagulation reversal against the risk of valve thrombosis or embolism from delayed resumption. Reversal with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma can be lifesaving, but optimal timing of reinitiation remains uncertain [2,3]. Case Description A 77‐year‐old male with atrial fibrillation and a mechanical mitral valve on warfarin presented with progressive aphasia. INR was 3.87, and head CT showed an acute right frontal parietal ICH. He received intravenous vitamin K and fresh frozen plasma, lowering his INR to 1.3. Anticoagulation was withheld for two weeks to reduce risk of hematoma expansion. During this period, repeat imaging demonstrated stability, and the patient remained clinically unchanged. Warfarin was reintroduced at two weeks, with INR values of 1.2, 1.5, and 2.5 on days 4, 7, and 12. He tolerated therapy without recurrent hemorrhage, thromboembolism, or valve dysfunction. At three months, he remained stable without new neurologic or cardiovascular events. Discussion Managing anticoagulation after warfarin‐related ICH requires individualized assessment. Although ICH can be fatal, reversal with vitamin K, PCC, or plasma is effective [3]. The greater challenge is determining when to restart therapy. Evidence suggests that resumption does not markedly increase recurrent ICH risk and may reduce mortality [4]. Timing strategies vary, with some advocating <2 weeks and others >4 weeks. For patients with MHVs and atrial fibrillation, annual thromboembolic risk exceeds 10% without anticoagulation [5]. In this case, multidisciplinary consensus supported restarting warfarin at two weeks, based on hematoma stability, high embolic risk, and close INR monitoring. Conclusion This case illustrates the complex balance of anticoagulation management in MHV patients with warfarin‐related ICH. Restarting therapy at two weeks proved safe, preventing both hemorrhagic recurrence and thromboembolic complications. Further studies are needed to clarify optimal timing. 1. Flaherty ML, Haverbusch M, Sekar P, et al. Long‐term mortality after intracerebral hemorrhage. Neurology . 2006;66(8):1182‐1186. 2. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin‐associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc . 2007;82(1):82‐92. 3. Steiner T, Bösel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke . 2010;41(2):402‐409. 4. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulation resumption in patients with anticoagulation‐related intracerebral hemorrhage. JAMA . 2015;313(8):824‐836. 5. Romualdi E, Micieli E, Ageno W, Squizzato A. Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review. Thromb Haemost . 2009;101(2):290‐297.